AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Antex Biologics plans six clinical trials in 2002.(Brief Article)
2002 JUN 26 - (NewsRx.com & NewsRx.net) -- Antex Biologics, Inc., (ANX) announced plans for additional clinical trials of its vaccine and antibiotic products and also announced financial results for its first quarter of 2002. The company has two products currently in human clinical trials and plans to have four additional products in clinical trials during the year.
Antex's current clinical trials are for two components of its Activax multivalent vaccine against contaminated food and water diseases. A phase II trial for the Campylobacter component of Activax is being conducted in conjunction with the U.S. Navy in anticipation of a phase III trial next year; and a phase I trial for the Shigella component is being conducted at the Johns Hopkins University vaccine testing unit in Baltimore. These trials should be completed by the end of the year.
Antex is currently manufacturing clinical material for its Helivax whole cell vaccine against Helicobacter pylori infections and for its Tracvax subunit vaccine against Chlamydia trachomatis infections. Helivax will begin a phase II trial later this summer and Tracvax a phase I trial in the fall. Additionally, the company's partner has completed phase I trials in children and infants for a pediatric middle ear infection (otitis media) vaccine; based on the results of these trials, the next evaluation will be a phase II trial.
Antex has manufactured a cGMP batch of AP-158, its lead antibiotic product, and the initial toxicology and pharmacology preclinical studies have been successfully completed. A phase II human clinical trial will be ...
- POZEN Inc. Releases Third-Quarter Results; Begins Two Clinical Trials.
- Press release article from: PR Newswire October 25, 2001 700+ words
...three Phase III clinical trials nearing completion. POZEN's net loss attributable to...basic and diluted net loss per common share and pro forma net loss per common share...two significant clinical trials in the third quarter...
- KeraVision, Inc. releases six month financial statement; investigational...
- Press release article from: Business Wire September 14, 1995 700+ words
...to higher costs for clinical trials and patent coverage...related technology. The net loss for the second quarter...currently in FDA Phase II clinical trials. -0- Condensed Statement...expense -- -- -- (60) Net loss $(1,556) $(2...
- San Antonio Pharmaceutical Firm Reports Net Loss of $62.1 Million.
- Newspaper article from: San Antonio Express-News (San Antonio, TX) January 28, 2004 700+ words
...a former client, the net loss for 2003 would have been...quarter, Ilex reported a net loss of $17.8 million on...money into additional clinical trials on Campath and several other drugs, 2004's net loss is expected to top...
- Gaithersburg-based GenVec's net loss widens.(Financial report)
- Newspaper article from: Daily Record (Baltimore, MD) May 10, 2007 700+ words
...Staff & Wire Reports Costly clinical trials for its pancreatic cancer treatment candidate widened GenVec Inc.'s net loss for the first quarter to $6 million...or 6 cents per diluted share, net loss for the similar period last year...
- Cardiovascular drug maker reports a net loss of $5.2M.
- Newspaper article from: Biotech Week December 18, 2002 700+ words
...SAPPHIRE and SILVER clinical trials. For the 9 months...Alteon had a net loss of $13,799...SAPPHIRE and SILVER clinical trials. The noncash...861,000. The net loss for both the...SAPPHIRE and SILVER clinical trials of ALT-711...
- deCODE's FY 2006 net loss deepens 36.1%.(Financial report)
- Newspaper article from: Pharma Marketletter March 19, 2007 700+ words
...However, its net loss worsened to $85...to the cost of clinical trials in the company...Basic and diluted net loss per share was...predictions, though net loss exceeded their...reflecting the cost of clinical trials in its heart attack...
- Pharmaceutical company reports net loss of $4.4M.
- Newspaper article from: Biotech Week December 25, 2002 700+ words
...related to funding clinical trials, expanding research...actively engaged in clinical trials. We expect our operating...when we begin human clinical trials, which are targeted...half of 2003." The net loss for the 9 months ended...
- Radiance Reports 41 Percent Increase in Revenues and 42 Percent Reduction in...
- Press release article from: Business Wire July 20, 2000 700+ words
...The decrease in net loss for the second...higher spending for clinical trials and research and...the company's net loss was $2,618...decrease in the net loss for the first six...though spending for clinical trials and research and...
- ENDOVASCULAR TECHNOLOGIES ANNOUNCES FIRST QUARTER 1996 FINANCIAL RESULTS...
- Press release article from: PR Newswire April 17, 1996 700+ words
...944 as compared to a net loss of $2,061,370 for the first quarter of 1995. Net loss per share of $0.35...1996 compares to a net loss per share of $0.33...includes the cost of clinical trials. EVT's cash, cash...
- KeraVision, Inc. Releases 1995 Year End and Fourth Quarter Results;...
- Press release article from: Business Wire February 15, 1996 700+ words
...today reported a net loss of $7.1 million...as compared to a net loss of $6.1 million...higher costs for clinical trials and patent coverage...in FDA Phase II clinical trials. -0- NOTE TO...57) (114) Net loss $(1,792...
Source: HighBeam Research, Antex Biologics plans six clinical trials in 2002.(Brief Article)